Bei Akademie registrieren
Novartis, CH0012005267

Novartis reports trial data as Novartis stock trades at EUR 135.50

Published on 10/25/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock costs EUR 135.50 in weekend trading on October 25, 2026. Novartis reported two Phase III trial updates.

Late-stage trial updates

  • Novartis presented Phase III multiple-sclerosis results on October 23, 2026.
  • Novartis stock trades in weekend trading at Lang & Schwarz at EUR 135.50 at 5:17 p.m. CEST on October 25, 2026.
  • The next Xetra session is scheduled for October 26, 2026.
  • Kisqali plus endocrine therapy reduced the reported risk of death by 19.1 percent in the six-year NATALEE analysis.
Börsenanzeigetafel mit Candlestick-Charts und Händlern auf einem Schweizer Handelsparkett
Novartis AG CH0012005267 – Börsentafel mit Pharmacharts und Händlern auf belebtem Schweizer Trading-Floor, Illustration mit AI erstellt.

Novartis reported two Phase III trial updates on October 23, 2026, while Novartis stock was quoted at EUR 135.50 in weekend trading at Lang & Schwarz at 5:17 p.m. CEST. The company’s remibrutinib release described results from the REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, while a separate release reported six-year NATALEE results for Kisqali in early breast cancer. The trial announcements were published by GlobeNewswire via Ritzau and GlobeNewswire via Ritzau.

Market context: Market report SMI.

The week in figures

At 5:17 p.m. CEST on October 25, 2026, the Lang & Schwarz weekend-trading indication for Novartis stood at EUR 135.50. Xetra and the primary exchanges were closed during the weekend-trading phase.

The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.

Chronology of the week

On October 23, 2026, Novartis said remibrutinib reduced annualized relapse rates versus teriflunomide by 35.2 percent in REMODEL-1 and 31.2 percent in REMODEL-2, according to the company release.

Also on October 23, 2026, Novartis reported that Kisqali plus endocrine therapy reduced the risk of death by 19.1 percent versus endocrine therapy alone in the six-year NATALEE analysis, according to the company release.

Dates of the coming week

The next Xetra session is scheduled for October 26, 2026. Novartis has scheduled its results publication for October 27, 2026, according to the company topic page.

Disclaimer...
en | CH0012005267 | NOVARTIS | boerse | 70409918 | bgmi